Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis

NCT ID: NCT01125410

Last Updated: 2010-05-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

321 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical study was to evaluate whether vaginal tablets containing 10 mg dequalinium chloride (Fluomizin) are comparable in clinical efficacy and safety to clindamycin vaginal cream (2%) in patients suffering from bacterial vaginosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An international, multi-center, single-blind, randomized, active-controlled study with two parallel groups in patients with bacterial vaginosis. Eligible patients were randomized to receive Fluomizin vaginal tablets for 6 days or Clindamycin vaginal cream (2%) for 7 days. Control examinations were performed 3 to 14 days and 2 to 6 weeks after the end of the therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Vaginosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dequalinium chloride 10mg

Group Type EXPERIMENTAL

Dequalinium chloride

Intervention Type DRUG

Vaginal tablet, 10mg, 1 tablet daily for 6 days

clindamycin vaginal cream 2%

Group Type ACTIVE_COMPARATOR

Clindamycin

Intervention Type DRUG

vaginal cream, 2%, once daily for 7 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dequalinium chloride

Vaginal tablet, 10mg, 1 tablet daily for 6 days

Intervention Type DRUG

Clindamycin

vaginal cream, 2%, once daily for 7 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of bacterial vaginosis
* Women aged 18-55 years

Exclusion Criteria

* Pregnancy or lactation
* Uterine bleeding (including menstruation but not including cervical contact bleeding on sampling) or vaginal bleeding of unknown origin
* Acute infections of the upper genital tract
* Clinical Symptoms of a vulvovaginal Candidiasis
* Use of anti-infectives (local or systemic) in the previous 14 days and/or during the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medinova AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Medinova AG

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ernst Rainer Weissenbacher, MD

Role: PRINCIPAL_INVESTIGATOR

Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU Munich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AZ Imelda Ziekenhuis

Bonheiden, , Belgium

Site Status

AZ St. Dimpna

Geel, , Belgium

Site Status

AZ Ziekenhuis Oost-Limburg

Genk, , Belgium

Site Status

AZ Heilig Hart

Tienen, , Belgium

Site Status

Centrum Ambulantni gynekologie a prodnictvi

Brno, , Czechia

Site Status

Faculty Hospital Brno

Brno, , Czechia

Site Status

University Hospital Hradec Kralove

Hradec Králové, , Czechia

Site Status

Charles University

Prague, , Czechia

Site Status

Fakultni nemocnice Na Bulovce

Prague, , Czechia

Site Status

Ambulance pro gynekologie a prodnictvi

Telč, , Czechia

Site Status

LMU Munich

Munich, , Germany

Site Status

JLF UK a MFN

Martin, , Slovakia

Site Status

University Hospital of Geneva and Faculty of Medicine

Geneva, , Switzerland

Site Status

CHUV

Lausanne, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Czechia Germany Slovakia Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Weissenbacher ER, Donders G, Unzeitig V, Martinez de Tejada B, Gerber S, Halaska M, Spacek J; Fluomizin Study Group. A comparison of dequalinium chloride vaginal tablets (Fluomizin(R)) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest. 2012;73(1):8-15. doi: 10.1159/000332398. Epub 2011 Dec 24.

Reference Type DERIVED
PMID: 22205034 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Med380104

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacokinetics of Transdermal Metronidazole
NCT05929794 ACTIVE_NOT_RECRUITING PHASE4
Safety and Efficacy of Moxidex Otic
NCT01071902 TERMINATED PHASE3